Changes in cytokine`s levels were statistically increased after the PTX treatment of breast cells (p < 0.0001), suggesting the influence of this anti-tumor drug to interfere with NLRP3 inflammasome activation and pro-inflammatory mediators secretion in TNBC MDA-MB-231 cells. Here, NLRP3 is linked to neoplasm.